Company: CERO
Filing Date: 2025-08-22
Form Type: 10-Q
Source: 0001213900-25-079898
Chunk: 2

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 10-Q
Item: Item 1
Chunk 2
---
202,322  
    $6,206,929 

See
accompanying notes to the condensed consolidated financial statements

Reflects
a 1-for-100 reverse stock split effective January 8, 2025 and 1-for-20 reverse stock split effective June 13, 2025

1

CERO
THERAPEUTICS HOLDINGS, INC.

CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

    For the
 Three Months
 Ended
 June 30,
 2025  
    For the
 Three Months
 Ended
 June 30,
 2024  
    For the
 Six Months
 Ended
 June 30,
 2025  
    For the
 Period from
 February 14,
 2024
 through
 June 30,
 2024  
    For the
 Period from
 January 1,
 2024
 through
 February 13,
 2024 

    (Successor)  
    (Successor)  
    (Successor)  
    (Successor)  
    (Predecessor) 
  
    Operating expenses: 

    Research and development 
    $2,753,963  
    $2,714,344  
    $5,661,790  
    $3,618,359  
    $764,192 
  
    General and administrative 
     1,969,828  
     2,433,893  
     4,012,532  
     5,184,815  
     132,941 
  
    Total operating expenses 
     4,723,791  
     5,148,237  
     9,674,322  
     8,803,174  
     897,133 
  
    Loss from operations 
     (4,723,791) 
     (5,148,237) 
     (9,674,322) 
     (8,803,174) 
     (897,133)

    Other income (expenses): 

    Gain from settlement of liabilities with vendors 
     -  
     447,335  
     -  
     589,223  
     - 
  
    Other expenses 
     -  
     (630,775) 
     -  
     (